NervGen to Detail Function Improvement Data at Spinal Cord Injury Symposium

Event summary

  • NervGen Pharma will present clinical data from the Phase 1b/2a CONNECT SCI Study at Unite2Fight Paralysis’ symposium on February 15, 2026.
  • The presentation, featuring CEO Adam Rogers, will focus on durable improvements in function, independence, and quality of life observed in chronic spinal cord injury patients.
  • The symposium, held in Washington, DC, brings together scientists, clinicians, policymakers, and patient advocates.
  • NervGen’s lead candidate, NVG-291, is a subcutaneously administered peptide and has received Fast Track and Orphan Drug designations.

The big picture

NervGen's progress represents a significant, albeit early, step toward a pharmacologic treatment for spinal cord injury, a market with substantial unmet need and limited therapeutic options. The company’s focus on durable improvements in quality of life, rather than just motor function, aligns with a growing patient-centric approach in drug development. The symposium provides a crucial platform for NervGen to engage with key stakeholders and influence the evolving treatment landscape.

What we're watching

Clinical Validation
The specifics of the data presented at the symposium will be critical in assessing the clinical significance of NVG-291’s observed improvements, particularly given the chronic nature of the patient population.
Regulatory Pathway
How the FDA and EMA interpret the CONNECT SCI data will heavily influence the design and potential success of future Phase 3 trials and the overall commercial viability of NVG-291.
Competitive Landscape
The presentation’s reception within the spinal cord injury research community will reveal how NervGen’s approach stacks up against emerging therapies and alternative treatment paradigms.